Not only is this this three-stage competition free to enter, it’s also the only pharmaceutical sales awards where representatives are evaluated by their healthcare professional clients, before pitting them head-to-head in a real life challenge against their peers.
The PharmaTimes Communications Team of the year competition is now open for entry, with two new categories offering yet more opportunities for forward thinking agencies!
The PharmaTimes International Clinical Researcher of the Year Awards Ceremony & Gala Dinner is to take place next Thursday (17 May) at the Millenium Gloucester Hotel in London’s Kensington.
Janssen’s Tremfya has been recommended by NICE as a cost-effective treatment for plaque psoriasis.
Eli Lilly is buying ARMO BioSciences in a deal valued at around $1.6 billion, to ramp up its immune-oncology pipeline.
Scientists have made a major discovery having identified a mutation that gives cancer cells resistance to AstraZeneca’s Lynparza and other PARP inhibitors.
Akcea Therapeutics’ volanesorsen has taken a step closer to becoming the first therapy on the US market for the ultra-rare rare lipid disorder familial chylomicronemia syndrome (FCS).
A study published in the British Journal of General Practice has found that it is becoming increasingly difficult for patients to get appointments with their GP of choice.
US regulators have rejected Lipocine’s Tlando, a testosterone replacement therapy for adult males with hypogonadism.
Roche has revealed that a combination of Tecentriq and Cotellic tested in a late-stage trial failed to improve overall survival compared to regorafenib in patients with advanced metastatic colorectal cancer (CRC).
GlaxoSmithKline has announced that its chief financial officer Simon Dingemans is to retire.
The government has taken a u-turn on controversial data-sharing arrangements under which the NHS was able to hand over patient details to the Home Office for immigration tracking purposes.
Takeda is moving ahead with its quest to acquire UK-listed Shire, after the latter approved an offer equating to around £46 billion.
European regulators have approved a tablet formulation and new dosing regimen for AstraZeneca and MSD’s Lynparza to treat a wider range of patients with ovarian cancer.
NHS England has unveiled new processes designed to fast track clinical trials undertaken across the NHS, and boost access for patients.
